Literature DB >> 11483777

Human T-cell leukemia virus type 1 receptor expression among syncytium-resistant cell lines revealed by a novel surface glycoprotein-immunoadhesin.

S R Jassal1, R G Pöhler, D W Brighty.   

Abstract

The envelope glycoproteins of human T-cell leukemia virus type 1 (HTLV-1) perform functions that are crucial for virus entry into cells. The surface glycoprotein (SU) is responsible for viral recognition of, and binding to, target cells through its interaction with an unknown cell surface receptor. To facilitate molecular analysis of the receptor-binding properties of SU and to characterize the cellular receptor employed by HTLV-1, we have expressed a recombinant SU fused to the Fc domain of human immunoglobulin G. Here, we demonstrate that this novel SU-immunoadhesin retains both the biochemical properties of Fc and the receptor-binding specificity of the HTLV-1 SU. We use this SU-immunoadhesin to demonstrate, by direct cell surface binding assays, that the receptor used by HTLV-1 has been conserved through vertebrate evolution. Moreover, using murine-human somatic cell hybrids we provide data that do not support the previously assigned location for the HTLV-1 receptor on human chromosome 17. Most importantly, we show that many cell lines that are resistant to HTLV-1 envelope-mediated infection and syncytium formation express functional receptors that are recognized by the HTLV-1 SU. Based on our results, we suggest that for some HTLV-1-resistant cell lines the block to viral entry occurs at a late post-receptor-binding step of the entry process. Our findings will be of value in developing new strategies to identify the cellular receptor used by HTLV-1.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11483777      PMCID: PMC115076          DOI: 10.1128/jvi.75.17.8317-8328.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  The ectodomain of the human T-cell leukemia virus type 1 TM glycoprotein is involved in postfusion events.

Authors:  A R Rosenberg; L Delamarre; C Pique; D Pham; M C Dokhélar
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 2.  Human T-cell lymphotropic viruses.

Authors: 
Journal:  IARC Monogr Eval Carcinog Risks Hum       Date:  1996

3.  Identification of a domain within the human T-cell leukemia virus type 2 envelope required for syncytium induction and replication.

Authors:  B Poon; I S Chen
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

4.  A novel human T-leukemia virus type 1 cell-to-cell transmission assay permits definition of SU glycoprotein amino acids important for infectivity.

Authors:  L Delamarre; A R Rosenberg; C Pique; D Pham; M C Dokhélar
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

5.  Human T-cell lymphotropic virus type 1 (HTLV-1)-induced syncytium formation mediated by vascular cell adhesion molecule-1: evidence for involvement of cell adhesion molecules in HTLV-1 biology.

Authors:  J E Hildreth; A Subramanium; R A Hampton
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

6.  71-kilodalton heat shock cognate protein acts as a cellular receptor for syncytium formation induced by human T-cell lymphotropic virus type 1.

Authors:  Y Sagara; C Ishida; Y Inoue; H Shiraki; Y Maeda
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

7.  Analysis of functional conservation in the surface and transmembrane glycoprotein subunits of human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2.

Authors:  A R Rosenberg; L Delamarre; A Preira; M C Dokhélar
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

8.  Broad host range of human T-cell leukemia virus type 1 demonstrated with an improved pseudotyping system.

Authors:  R E Sutton; D R Littman
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

9.  Seroepidemiology of the human T-cell leukaemia/lymphoma viruses in Europe. The HTLV European Research Network.

Authors: 
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1996-09

10.  Syncytium-inhibiting monoclonal antibodies produced against human T-cell lymphotropic virus type 1-infected cells recognize class II major histocompatibility complex molecules and block by protein crowding.

Authors:  J E Hildreth
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

View more
  17 in total

1.  Human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2 use different receptor complexes to enter T cells.

Authors:  Kathryn S Jones; Kazunori Fugo; Cari Petrow-Sadowski; Ying Huang; Daniel C Bertolette; Ivonne Lisinski; Samuel W Cushman; Steven Jacobson; Francis W Ruscetti
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  Heparan sulfate proteoglycans mediate attachment and entry of human T-cell leukemia virus type 1 virions into CD4+ T cells.

Authors:  Kathryn S Jones; Cari Petrow-Sadowski; Daniel C Bertolette; Ying Huang; Francis W Ruscetti
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

3.  Conformation-specific antibodies targeting the trimer-of-hairpins motif of the human T-cell leukemia virus type 1 transmembrane glycoprotein recognize the viral envelope but fail to neutralize viral entry.

Authors:  Antonis Mirsaliotis; Kulpash Nurkiyanova; Daniel Lamb; Jenny M Woof; David W Brighty
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103

4.  Similar regulation of cell surface human T-cell leukemia virus type 1 (HTLV-1) surface binding proteins in cells highly and poorly transduced by HTLV-1-pseudotyped virions.

Authors:  Kathryn S Jones; Manisha Nath; Cari Petrow-Sadowski; Andrea C Baines; Megan Dambach; Ying Huang; Francis W Ruscetti
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

5.  An antiviral peptide targets a coiled-coil domain of the human T-cell leukemia virus envelope glycoprotein.

Authors:  Josefina D Piñón; Sharon M Kelly; Nicholas C Price; Jack U Flanagan; David W Brighty
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

6.  Candidate polyanionic microbicides inhibit human T-cell lymphotropic virus type 1 receptor interactions, cell-free infection, and cell-cell spread.

Authors:  Daniela Romer; David W Brighty; Cynthia L Robson; Quentin J Sattentau
Journal:  Antimicrob Agents Chemother       Date:  2008-12-01       Impact factor: 5.191

7.  The receptor complex associated with human T-cell lymphotropic virus type 3 (HTLV-3) Env-mediated binding and entry is distinct from, but overlaps with, the receptor complexes of HTLV-1 and HTLV-2.

Authors:  Kathryn S Jones; Ying K Huang; Sébastien A Chevalier; Philippe V Afonso; Cari Petrow-Sadowski; Daniel C Bertolette; Antoine Gessain; Francis W Ruscetti; Renaud Mahieux
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

8.  Bovine leukemia virus SU protein interacts with zinc, and mutations within two interacting regions differently affect viral fusion and infectivity in vivo.

Authors:  Jean-Stéphane Gatot; Isabelle Callebaut; Carine Van Lint; Dominique Demonté; Pierre Kerkhofs; Daniel Portetelle; Arsène Burny; Luc Willems; Richard Kettmann
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

9.  Human T-cell leukemia virus type 1 envelope glycoprotein gp46 interacts with cell surface heparan sulfate proteoglycans.

Authors:  Josefina D Piñon; P J Klasse; Sushma R Jassal; Sandy Welson; Jonathan Weber; David W Brighty; Quentin J Sattentau
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

10.  Nonhelical leash and alpha-helical structures determine the potency of a peptide antagonist of human T-cell leukemia virus entry.

Authors:  Antonis Mirsaliotis; Daniel Lamb; David W Brighty
Journal:  J Virol       Date:  2008-02-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.